赞科

最新新闻

• 评级变动
  BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• 评级变动
  CCORF Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  TD Cowen Maintains Xencor(XNCR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  Truist Financial Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• Barclays Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  J.P. Morgan Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  Barclays Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $27
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $20 to $44
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Piper Sandler Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  William Blair Maintains Xencor(XNCR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• Truist Financial Maintains Xencor(XNCR.US) With Buy Rating, Announces Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Truist Financial Maintains Xencor(XNCR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• Raymond James Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $46
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen Inc. (PEPG)
  TipRanks · 2026/8/6
• 评级变动
  Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
  TipRanks · 2026/5/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。